Article Text

Download PDFPDF
Pure malignant immature teratoma of the ovary: the role of chemotherapy and second-look surgery
  1. S. Culine*,
  2. C. Lhomme*,
  3. J. Kattan*,
  4. G. Michel,
  5. P. Duvillard and
  6. J. P. Droz§
  1. * Department of Medicine,
  2. Department of Surgery,
  3. Department of Pathology, Institut Gustave Roussy, Villejuif; and
  4. § Department of Medical Oncology, Centre Leon Berard, Lyon, France
  1. Address for correspondence: Dr S. Culine, Centre Regional Val D'Aurelle 34298, Montpellier Cedex 5, France.


Fifteen patients with pure malignant immature teratoma of the ovary were treated at the Institut Gustave Roussy over a 17-year period. Chemotherapy was delivered as primary postoperative therapy in 11 patients. Four other patients received chemotherapy as part of their salvage treatment for recurrent disease. A second-look laparotomy was performed in eight patients. Histological findings were: no tumor in three patients, mature teratoma in four patients, and immature grade 1 teratoma in one patient. The latter five patients had persistent radiologic abnormalities at the end of chemotherapy. Twelve patients remain free of disease 24–228 months from initiation of chemotherapy. Two children were delivered from the two patients who attempted pregnancy. All three patients who died of progressive disease had a grade 3 immature teratoma. We conclude that the treatment of pure immature teratoma of the ovary should include primary conservative surgery and cisplatin-based chemotherapy. Second-look surgery is mandatory in patients with persistant radiologic abnormalities at the completion of chemotherapy.

  • chemotherapy
  • germ cell
  • immature teratoma
  • ovary
  • second-look laparotomy.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.